Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Resonance Health Ltd ( (AU:RHT) ) just unveiled an announcement.
Resonance Health Ltd has reported a significant financial upturn, with record cash receipts of $5 million for the last quarter, marking a 57% increase from the previous quarter. This growth is driven by successful execution of clinical trials, including a new $13.8 million trial, and expansion of its TrialsWest sites. The company continues to enhance its operations with the introduction of new services, such as a central-read analysis for Magnetic Resonance Elastography, and the development of an MRI Liver Fibrosis product. These advancements position Resonance Health as a formidable player in the medical technology sector, promising further growth and increased capacity to serve major pharmaceutical clients.
More about Resonance Health Ltd
Resonance Health Ltd operates in the medical technology industry, focusing on three primary business areas: Software-as-a-Medical Device (SaMD), Clinical Trial Management (CRO Services), and Clinical Trial Site Services (TrialsWest). The company is known for its innovative solutions in diagnostics and clinical trials, catering to various pharmaceutical clients and emphasizing growth and operational efficiency in its market focus.
YTD Price Performance: 0%
Average Trading Volume: 390,200
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$23.9M
Find detailed analytics on RHT stock on TipRanks’ Stock Analysis page.
